Illumina

In the first quarter of 2026, we accelerated our strategy across AI insights, genomic and multiomic innovation, and clinical strength. Here are the highlights 👇    🔶 Unlocking speed and scale for drug discovery: We introduced the Billion Cell Atlas, the most comprehensive map of human disease biology to help train the next generation of AI models for drug target identification.    🔶 Driving the insight ecosystem: With the launch of TruPath™ Genome we delivered the simplest workflow for comprehensive whole-genome variant detection. We also unveiled a roadmap of NovaSeq™ X advancements including Q70 accuracy + 35B flow cells, and our customers shared new data that illustrates the impact of our multiomics portfolio.     🔶 Strengthening customer access to proteomic insights at scale: We officially welcomed the SomaLogic team to Illumina, helping customers generate rich multiomic datasets in support of better outcomes for patients.     🔶 Advancing our global clinical strategy: Dr. Eric Green joined Illumina as Chief Medical Officer to help advance the clinical use of genomics, expand access to precision medicine solutions, and increase the diversity of genomics data. Learn more at https://www.illumina.com/

What does it take to power the next wave of AI-driven drug discovery? Biological data—at an entirely new scale. The Billion Cell Atlas is designed to deliver just that: a first-of-its-kind resource built to train AI models for precision medicine and drug target identification. Hear directly from Kyle Kai-How Farh MD PhD , VP & Distinguished Scientist at Illumina, and explore the full story: https://lnkd.in/guhpN4nz

🎥 In celebration of #DNADay, Illumina employees around the world went back to the classroom to show students how genomics can help address global challenges. 🧬 Through hands‑on science and career conversations, employees connected thousands of learners with the people behind the science—helping make careers in genomics feel more personal and possible. What made this campaign especially meaningful was the collective participation: educators welcomed volunteers into their learning spaces, and students showed up with curiosity, enthusiasm, and excitement about what a future in STEM could look like. The future is bright indeed, and we can’t wait to see how the STEM leaders of tomorrow help expand access to genomic breakthroughs around the world. Happy DNA Day! Learn more at: dnaday.org

🎥 Just how easy is TruPath™ Genome? We sent Illumina’s Chief Medical Officer Eric Green, M.D., Ph.D. back to the bench to try it for himself. At Illumina Lab Services, Dr. Green rose to the challenge—sharing a few laughs along the way—to demonstrate the unprecedented simplicity of a product that unlocks a whole new standard for genomic insights. Learn more about TruPath™ Genome: https://lnkd.in/g5eUT56H

Pushing the boundaries of cancer research, one discovery at a time. We recently attended #AACR26, where we showcased our latest advancements in single-cell, spatial, and multiomics technologies and how they’re accelerating translational research and drug discovery. Insights from leaders like Richard Capper, Stewart Comer, Jing Gao, Severine Catreux, Kyle Kai-How Farh MD PhD, Bodour Salhia, Ph.D, David Spencer, and Claire Mills, DDS highlighted how we’re scaling multiomics for deeper biological understanding and enabling the next wave of breakthroughs in cancer research. As we look ahead, we're focused on advancing scalable, integrated solutions that empower researchers to translate complex biology into life-saving impact.

At #AACR26, Illumina customers continued asking bolder, more complex scientific questions—so we're launching a new research grant to fuel that creativity and spotlight methylation 🧬 Our 5-Base Solution for Cancer Research Grant Contest promotes epigenetic research in oncology by providing access to Illumina’s integrated dualomic solution, 5-Base. The grant winner will receive Illumina 5-Base DNA Prep or Illumina 5-Base DNA Prep with Enrichment kits and core consumables to cover 1000 samples in pursuit of their research project. Learn more about eligibility and apply now—grant project proposals will be reviewed through June 26 🗓️ : https://lnkd.in/dWeCwKF2

Thousands of young students and researchers across China are learning how multiomics comes together to drive crucial insights — thanks to our new partnership 👇  We’re teaming up with the Genome Sequencing and Analysis Facility of the Technology Center for Protein Sciences at Tsinghua University to support IMPACT — the Innovative Life Science & Medical Practice Training Program. The two-year initiative blends theory with hands-on learning and helps young scientists build an end-to-end research approach and explore how pioneering new technologies can translate into real-world research practice.  The inaugural training workshop focused on single-cell sequencing with nearly 100 in-person participants, and 20,000 online viewers, and will expand over the next two years to include integrated analysis across genomics, single-cell, spatial transcriptomics, methylation, and proteomics. Learn more about the IMPACT program and how this collaboration is supporting the next generation of scientists: https://lnkd.in/dzjAVDux

🚀 Coming soon to a MiSeq i100 near you: faster microbial sequencing with new Rapid workflows enabling same-day answers. #ESCMIDGlobal2026 Designed to further simplify and accelerate pathogen detection, our new workflow improvements provide faster turnaround times—as short as ~6h from sample to answer—and improve yield of rare, low-abundance targets.  🔎 The new Rapid RNA Prep Kit uses a “one-pot” reaction, increasing sensitivity to deliver more robust and reliable results.  ⏱️ The MiSeq i100 Series 100-cycle kit Turbo Custom Recipe reduces sequencing time by 40%, allowing labs to reduce turnaround times by ~2h and perform more runs per day. Both workflows will be available for customers soon. “Truly impressed,” shared Professor Judith Breuer’s team at the Great Ormond Street Hospital. They had the chance to test the Rapid RNA Prep as part of the Respiratory Pathogen ID/AMR Enrichment Panel along with the Turbo Custom Recipe on the MiSeq i100 for rapid sequencing-based pathogen and AMR detection. 👇

📸 We kicked off #AACR26 at Illumina HQ with healthcare researchers, laboratory professionals, and oncology pioneers exploring how AI-powered informatics and multiomics are redefining cancer discovery.     Attendees got an under-the-hood look at our roadmap, a real-world view on scaling multiomics, and perspectives from Illumina leaders. We shared how integrated oncology and multiomic workflows are pushing the boundaries of translational research and drug discovery. Featuring insights from Cande Rogert, Stewart Comer, Jing Gao, Severine Catreux, Kyle Kai-How Farh MD PhD and Bodour Salhia, Ph.D. At #AACR26 this weekend? Stop by Booth 4727 to continue the conversation and learn more about all our oncology and multiomic research products: https://lnkd.in/gMCTQphR

The convergence of AI and genomics is making earlier cancer detection and improved outcomes possible — and we’re committed to supporting the next generation of academic researchers advancing precision oncology for patients everywhere. Just in time for #AACR26, learn more about the Illumina/Moores Cancer Center Fellowship in AI and Precision Oncology 👇